Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Ma, Y. [1 ]
Zhao, H. [1 ]
Zhao, Y. [2 ]
Cheng, Y. [3 ]
Cui, J. [4 ]
Liu, G. [5 ]
Xiong, D. [6 ]
Zhang, J. [5 ]
Xu, L. [7 ]
Yu, J. [5 ]
Men, L. [7 ]
Liang, E. [8 ]
Yang, D. [5 ]
Zhang, L. [1 ]
Zhai, Y. [9 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Zhengzhou Univ, Dept Med Oncol, Henan Canc Hosp, Canc Hosp, Zhengzhou, Peoples R China
[3] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[4] First Hosp Jilin Univ, Dept Oncol, Changchun, Peoples R China
[5] Ascentage Pharma Suzhou Co Ltd, Clin Res, Suzhou, Peoples R China
[6] Ascentage Pharma Suzhou Co Ltd, Preclin Res & Bio markers, Suzhou, Peoples R China
[7] Ascentage Pharma Suzhou Co Ltd, Biostat, Suzhou, Peoples R China
[8] Ascentage Pharma Grp Inc, Preclin Res & Biomarkers, Rockville, MD USA
[9] Ascentage Pharma Grp Inc, Clin Res, Rockville, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2351
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1317MO
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
    Kim, Chul
    Roper, Nitin
    Hoang, Chuong D.
    Wisch, Laura
    Connolly, Maureen
    Chou, Hsien-Chao
    Wei, Jun S.
    Tyagi, Manoj
    Cultraro, Constance
    Xi, Liqiang
    Waris, Maryam
    Szabo, Eva
    Padiernos, Emerson
    Kesarwala, Aparna Hemant
    Gao, Shaojian
    Steinberg, Seth M.
    Raffeld, Mark
    Rajan, Arun
    Khan, Javed
    Guha, Udayan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Characteristics of patients with EGFR-mutant non-small cell lung cancer (NSCLC) at a diverse metropolitan cancer center.
    Chen, Lanyi Nora
    Schluger, Benjamin
    Lagos, Galina
    Henick, Brian S.
    Herzberg, Benjamin
    Mathew, Matthen
    Shu, Catherine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
    Rotow, J.
    Urisman, A.
    Mccoach, C.
    Jahan, T.
    Bivona, T.
    Jones, K.
    Gupta, A.
    Do, H.
    Riess, J.
    Aisner, D.
    Doebele, R.
    Jablons, D.
    Kratz, J.
    Blakely, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S578 - S578
  • [44] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)
  • [45] A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).
    Li, Liu
    Qu, Jingjing
    Heng, Jianfu
    Zhou, Chunhua
    Xiong, Yi
    Yang, Haiyan
    Jiang, Wenjuan
    Zeng, Liang
    Zhu, Songlin
    Zhang, Yongchang
    Tan, Jiarong
    Hou, Ting
    Lizaso, Analyn
    Chen, Zhiqiu
    Hu, Chengping
    Deng, Pengbo
    Yang, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.
    Tan, Daniel Shao-Weng
    Leighl, Natasha B.
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Sequist, Lecia, V
    Toyozawa, Ryo
    Wolf, Juergen
    Felip, Enriqueta
    Kim, Sang-We
    Aix, Santiago Ponce
    Smit, Egbert F.
    Hida, Toyoaki
    Grohe, Christian
    Ghebremariam, Samson
    O'Sullivan-Djentuh, Leslie
    Belli, Riccardo
    Giovannini, Monica
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada
    Ezeife, Doreen A.
    Kirk, Veronica
    Chew, Derek S.
    Nixon, Nancy A.
    Lee, Roy
    Le, Lisa W.
    Chan, Kelvin K. -W.
    Leighl, Natasha B.
    LUNG CANCER, 2018, 125 : 1 - 7
  • [48] An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
    Shi, Yue
    Jiang, Yingying
    Pan, Banzhou
    Wang, Zihan
    Li, Hang
    Ma, Yuxin
    Liu, Yilin
    He, Kang
    Wang, Zhitong
    Lu, Jianwei
    Shi, Meiqi
    Shen, Bo
    Zhou, Guoren
    Yin, Rong
    Rossi, Antonio
    Ito, Kentaro
    Santarpia, Mariacarmela
    Um, Sang-Won
    Wang, Xiaohua
    Chen, Cheng
    Feng, Jifeng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 817 - 831
  • [49] Neurological death in patients with EGFR-mutant non-small cell lung cancer.
    Ramotar, Matthew
    Barnes, Sierra
    Doherty, Mark
    Shultz, David Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Cho, B. C.
    Lee, S. -H.
    Han, J. -Y.
    Cho, E. K.
    Lee, J. -S.
    Lee, K. H.
    Curtin, J. C.
    Gao, G.
    Xie, J.
    Schnepp, R. W.
    Bauml, J. M.
    Knoblauch, R. E.
    Thayu, M.
    Kim, D. -W.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S126 - S126
12345